Treating carbapenem-resistant Acinetobacter baumannii infections

Antibiotic treatment of patients with carbapenem-resistant Acinetobacter baumannii infection is one of the most controversial issues in the field of difficult-to-treat resistant Gram-negative bacteria management.1,2 Keith S Kaye and colleagues3 report results of a multinational randomised controlled trial (RCT) assessing the non-inferiority, with a margin of 20%, of sulbactam–durlobactam versus colistin, both given with imipenem–cilastatin, in the treatment of severe carbapenem-resistant A baumannii infections.